Navigation Links
Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
Date:10/20/2010

that T cells are involved in autoimmune diseases like Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis and others," noted Dr. Christopher Carlson, an investigator at the Fred Hutchinson Cancer Research Center and a co-founder of Adaptive TCR.  "Now we can examine what's going on in incredible detail, and hopefully we will find tests based on T-cell repertoires that give physicians prognostic information and treatment guidance."

ImmunoSEQ assays and the immunoSEQ Analyzer are easily available to any researcher.  The researcher or clinician need only provide a DNA sample; the company does all the laboratory work, and uploads the resulting sequence data to a secure web site that is available to the researcher at all times. "The true value to our clients lies in the combination of the assay with a user-friendly, powerful software suite for data analysis, visualization, and interpretation," adds CEO Robins.  

Robins believes that the industry is at the very beginning, "as our technology becomes increasingly powerful, we look forward to witnessing clients using immunoSEQ to answer fundamental questions in the field of adaptive immunity, leading to a better quality of life for people afflicted with dysfunctional immune systems."

About Adaptive TCR Corporation

Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR's proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand
'/>"/>

SOURCE Adaptive TCR Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies
2. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. Prometheus Research Launches Solutions Group to Springboard HTSQL-based Solutions for Customers
5. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
6. CoreLab Partners Launches New DXA Imaging Service Offerings
7. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
8. InSightec Launches ExAblate(R) One and ExAblate(R) OR Systems at CIRSE 2010
9. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
10. HelixLife Launches Custom Health Supplements, Anti-Aging and Acne Skin Serums
11. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 According ... Market by Data Center Types (Colocation, Enterprise, Telecom), ... Types (Tier 1, Tier 2, Tier 3, Tier ... MarketsandMarkets, defines and segments the Data Center Construction ... and forecasting of revenues. This research report also ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in minimally ... that its Board of Directors has appointed Dr. ... and member of the Board effective immediately. In ... responsibilities within the company, including further developing the ... manufacturing and finance. , Dr. Carol joined ...
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... 28, 2011 TriLink BioTechnologies, Inc. (TriLink) and Lucigen ... signed a licensing agreement for the use of TriLink,s ... MasterMix. TriLink,s CleanAmp™ dNTPs are an innovative ... standard dNTPs in a PCR assay with CleanAmp™ dNTPs, ...
... SILVER SPRING, Md., July 28, 2011 United Therapeutics Corporation ... for the quarter ended June 30, 2011. "I,m ... quarter, as well as the very good operating results we ... Executive Officer. "We remain on track to reach our 2011 ...
... Mass., July 27, 2011 SomaLogic, Inc. ... today that they have entered into an ... specific SOMAmers as critical and unique reagents ... acid amplification and polymerase chain reaction (PCR) ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 7Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... a non-traditional biophysics textbook and it describes how life ... of discovery into biological systems and provides an understanding ... is about how our genes make proteins that control ... cells in an organism. It quantifies the principles of ... be found on both large and small scales. The ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2
... NVIDIA CUDA Teaching Centre in Canada. The ... electrical and computer engineering students how to tap ... units (GPU) and use them in computationally demanding ... that enables dramatic increases in computing performance for ...
... successful initial testing of a new form of methotrexate ... nose drops rather than injected. It shows promise as a ... appears in ACS, Molecular Pharmaceutics , a bi-monthly journal. ... is difficult to treat, partly because current anticancer drugs have ...
... major risk factor for disease, much of the threat ... a cluster of risk factors related to diabetes and ... many of these risk factors. However, many people struggle ... the University of Missouri have found that people who ...
Cached Biology News:McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2Putting on the pounds after weight loss? Hit the gym to maintain health gains 2
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Alexa Fluor 647 anti-mouse Qa-2...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: